- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01799889
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies
November 2, 2020 updated by: Gilead Sciences
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
The primary objective of the study is to evaluate efficacy of entospletinib in participants with relapsed or refractory hematologic malignancies.
Participants with the following relapsed or refractory hematologic malignancies will be enrolled into the study: relapsed or refractory chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), or non-FL indolent non-Hodgkin lymphomas (iNHL; including lymphoplasmacytoid lymphoma/ Waldenström macroglobulinemia [LPL/WM], small lymphocytic lymphoma [SLL], or marginal zone lymphoma [MZL]).
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
326
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Barrie, Ontario, Canada, L4M 6M2
- Royal Victoria Regional Health Centre
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Sir Mortimer B. Davis-Jewish General Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama at Birmingham
-
-
Arizona
-
Tucson, Arizona, United States, 85710
- Arizona Oncology Associates
-
-
California
-
Duarte, California, United States, 91010
- City of Hope National Medical Center
-
San Diego, California, United States, 92123
- Sharp Memorial Hospital
-
-
Colorado
-
Boulder, Colorado, United States, 80303
- Rocky Mountain Cancer Centers, LLP
-
Denver, Colorado, United States, 80218
- Kaiser Permanente of Colorado
-
-
Connecticut
-
Southington, Connecticut, United States, 06489
- Cancer Center of Central Connecticut
-
-
Florida
-
Fort Myers, Florida, United States, 33905
- Florida Cancer - Colonial
-
Hollywood, Florida, United States, 33021
- Memorial Cancer Institute
-
Ocala, Florida, United States, 34471
- Ocala Oncology Center
-
-
Georgia
-
Atlanta, Georgia, United States, 30341
- Northside Hospital
-
Lawrenceville, Georgia, United States, 30046
- Gwinnett Hospital System Dba The Center for Cancer Care
-
Marietta, Georgia, United States, 30060
- Northwest Georgia Oncology Center
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University of Chicago
-
Niles, Illinois, United States, 60714
- Illinois Cancer Specialists
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University Simon Cancer Center
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70809
- Hematology Oncology Clinic, PLLC
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Tufts Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan Health System
-
Detroit, Michigan, United States, 48201
- Karmanos Cancer Institute
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55404
- Minnesota Oncology Hematology, PA
-
-
Mississippi
-
Hattiesburg, Mississippi, United States, 39401
- Hattiesburg Clinic
-
-
Nebraska
-
Omaha, Nebraska, United States, 68130
- Oncology Hematology West PC dba Nebraska Cancer Specialists
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
- One Medical Center Drive
-
-
New Jersey
-
Florham Park, New Jersey, United States, 07932
- Summit Medical Group, P.A.
-
-
New York
-
New York, New York, United States, 10021
- Clinical Research Alliance
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina
-
-
Ohio
-
Canton, Ohio, United States, 44718
- Gabrail Cancer Center Research
-
Cincinnati, Ohio, United States, 45242
- Oncology Hematology Care
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic
-
Columbus, Ohio, United States, 43210
- Ohio State University Comprehensive Cancer Center
-
-
Oregon
-
Springfield, Oregon, United States, 97477
- Williamette Valley Cancer Center and Research Institute
-
-
South Dakota
-
Watertown, South Dakota, United States, 57201
- Prairie Lakes Health Care System, Inc.
-
-
Tennessee
-
Germantown, Tennessee, United States, 38138
- Jones Clinic PC
-
Nashville, Tennessee, United States, 37203
- Tennessee Oncology, PLLC
-
-
Texas
-
Austin, Texas, United States, 78705
- Texas Oncology-Austin Midtown
-
Dallas, Texas, United States, 75230
- Texas Oncology-Medical City Dallas
-
Fort Worth, Texas, United States, 76104
- Center for Cancer and Blood Disorders
-
San Antonio, Texas, United States, 78217
- Cancer Care Network of South Texas
-
San Antonio, Texas, United States, 78229
- Cancer Care Center of South Texas
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Virginia Cancer Specialists, PC
-
Richmond, Virginia, United States, 23226
- Virginia Cancer Institute
-
-
Washington
-
Kennewick, Washington, United States, 99336
- Columbia Basin Hematology and Oncology
-
Seattle, Washington, United States, 98109
- University of Washington
-
Vancouver, Washington, United States, 98684
- Northwest Cancer Specialists, PC
-
Yakima, Washington, United States, 98902
- Yakima Valley Memorial Hospital North Star Lodge
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Key Inclusion Criteria:
- Diagnosis of B-cell iNHL, DLBCL, MCL, or CLL as documented by medical records and with histology based on criteria established by the World Health Organization
- For institutions that have Phase 3 or Phase 4 protocols studying idelalisib (Zydelig®) ; individuals with malignancies being studied in these protocols must have failed screening in the respective idelalisib protocol
- Prior treatment for lymphoid malignancy requiring treatment for progressive disease
- Presence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancy
- All acute toxic effects of any prior antitumor therapy resolved to Grade ≤ 1 before the start of study drug
- Karnofsky performance status of ≥ 60
- Life expectancy of at least 3 months
Key Exclusion Criteria:
- Known histological transformation from iNHL or CLL to an aggressive form of non-Hodgkin lymphoma (ie, Richter transformation) except if the CLL participant is enrolling in the BCR previously treated cohort
- Known active central nervous system or leptomeningeal lymphoma
- Presence of known intermediate- or high-grade myelodysplastic syndrome
- Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of start of study drug
- Ongoing liver injury
- Ongoing or recent hepatic encephalopathy
- Ongoing drug-induced pneumonitis
- Ongoing inflammatory bowel disease
- Ongoing alcohol or drug addiction
- Pregnancy or breastfeeding
- History of prior allogeneic bone marrow progenitor cell or solid organ transplantation
- Ongoing immunosuppressive therapy
- Concurrent participation in an investigational drug trial with therapeutic intent
NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CLL, Entospletinib MM/SDD
Participants with CLL, receive original formulation (mono-mesylate [MM]) of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib (spray dried dispersion [SDD]) 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily.
Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
|
Entospletinib MM tablet administered orally
Other Names:
Entospletinib SDD tablet administered orally
Other Names:
|
Experimental: FL, Entospletinib MM/SDD
Participants with FL, receive original formulation of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily.
Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
|
Entospletinib MM tablet administered orally
Other Names:
Entospletinib SDD tablet administered orally
Other Names:
|
Experimental: DLBCL, Entospletinib MM/SDD
Participants with DLBCL, receive original formulation of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily.
Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
|
Entospletinib MM tablet administered orally
Other Names:
Entospletinib SDD tablet administered orally
Other Names:
|
Experimental: MCL, Entospletinib MM/SDD
Participants with MCL, receive original formulation of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily.
Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
|
Entospletinib MM tablet administered orally
Other Names:
Entospletinib SDD tablet administered orally
Other Names:
|
Experimental: non-FL iNHL, Entospletinib MM/SDD
Participants with non-FL iNHL (ie, participants with LPL/WM, SLL, or MZL), receive original formulation of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily.
Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
|
Entospletinib MM tablet administered orally
Other Names:
Entospletinib SDD tablet administered orally
Other Names:
|
Experimental: CLL; Prior BCR Inhibitor Naive, Entospletinib SDD 100 mg
Participants with CLL, who are prior B-cell receptor (BCR) inhibitor naive, receive new formulation of entospletinib 100 mg (1 × 100 mg tablet) orally twice daily.
Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
|
Entospletinib SDD tablet administered orally
Other Names:
|
Experimental: CLL; Prior BCR Inhibitor Naive, Entospletinib SDD 200 mg
Participants with CLL, who are prior BCR inhibitor naive, receive new formulation of entospletinib 200 mg (1 × 200 mg tablet) orally twice daily.
Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
|
Entospletinib SDD tablet administered orally
Other Names:
|
Experimental: CLL; Prior BCR Inhibitor Naive, Entospletinib SDD 400 mg
Participants with CLL, who are prior BCR inhibitor naive, receive new formulation of entospletinib 400 mg (2 × 200 mg tablets) orally twice daily.
Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
|
Entospletinib SDD tablet administered orally
Other Names:
|
Experimental: CLL (Non-Richters) Prior BTK Inhibitor, Entospletinib SDD
Participants with CLL and simple progression (non-Richters), who are exposed to Bruton tyrosine kinase (BTK) inhibitor, receive new formulation of entospletinib 400 mg (2 × 200 mg tablets) orally twice daily.
Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
|
Entospletinib SDD tablet administered orally
Other Names:
|
Experimental: CLL (Non-Richters) Prior PI3K Inhibitor, Entospletinib SDD
Participants with CLL and simple progression (non-Richters), who are exposed to phosphatidylinositol 3-kinase (PI3K) inhibitor, receive new formulation of entospletinib 400 mg (2 × 200 mg tablets) orally twice daily.
Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
|
Entospletinib SDD tablet administered orally
Other Names:
|
Experimental: CLL (Richters) Prior BTK Inhibitor, Entospletinib SDD
Participants with CLL, who transform to Richters or Richters-like syndrome and are exposed to BTK inhibitor, receive new formulation of entospletinib 400 mg (2 × 200 mg tablets) orally twice daily.
Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
|
Entospletinib SDD tablet administered orally
Other Names:
|
Experimental: CLL (Richters) Prior PI3K Inhibitor, Entospletinib SDD
Participants with CLL, who transform to Richters or Richters-like syndrome and are exposed to PI3K inhibitor, receive new formulation of entospletinib 400 mg (2 × 200 mg tablets) orally twice daily.
Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
|
Entospletinib SDD tablet administered orally
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-Free Survival (PFS) Rate of Participants With CLL After BCR Targeted Therapy, MCL, and DLBCL at Week 16
Time Frame: Week 16
|
PFS rate was assessed by Independent Review Committee (IRC) and defined per standardized criteria (2007 Cheson criteria) (for NHL) and International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria (for CLL), as the percentage of participants not experiencing definitive progression or death.
Disease progression was defined per standardized criteria as: evidence of any new disease; worsening of nodal or extra-nodal index lesions; unequivocal increase in the size of non-index lesions or non-measurable disease, size of the liver, spleen, or other organ; and a ≥ 25% increase from nadir in either monoclonal immunoglobulin M (IgM) concentration or total serum IgM quantitation.
Disease progression was defined per standardized IWCLL criteria as: evidence of any new disease; worsening of index lesions, spleen or liver, or non-index disease; and decrease in platelet count or hemoglobin that is attributable to CLL.
PFS rate was analyzed using Kaplan-Meier (KM) estimates.
|
Week 16
|
PFS Rate of Participants With CLL (Including CLL, Prior BCR Inhibitor Naive Participants), FL, and Non-FL iNHL at Week 24
Time Frame: Week 24
|
PFS rate was assessed by IRC and defined per standardized criteria (2007 Cheson criteria) (for NHL) and IWCLL criteria (for CLL), as the percentage of participants not experiencing definitive progression or death.
Disease progression was defined per standardized criteria (2007 Cheson criteria) as: evidence of any new disease; worsening of nodal or extra-nodal index lesions; unequivocal increase in the size of non-index lesions or non-measurable disease, size of the liver, spleen, or other organ; and a ≥ 25% increase from nadir in either monoclonal IgM concentration or total serum IgM quantitation.
Disease progression was defined per standardized IWCLL criteria as: evidence of any new disease; worsening of index lesions, spleen or liver, or non-index disease; and decrease in platelet count or hemoglobin that is attributable to CLL.
PFS rate was analyzed using KM estimates.
|
Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Experiencing Treatment-Emergent Adverse Events
Time Frame: First dose date up to the last dose date plus 30 days (maximum: 78.4 months)
|
A treatment-emergent Adverse Event (AE) was defined as an AE that occurs in the period from the first dose of study treatment to 30 days after the last dose of study treatment or leads to discontinuation of study treatment.
Participants were assessed for AEs according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03.
|
First dose date up to the last dose date plus 30 days (maximum: 78.4 months)
|
Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher
Time Frame: First dose date up to the last dose date plus 30 days (maximum: 78.4 months)
|
Hematology toxicity at any time postbaseline was summarized according to the NCI CTCAE, version 4.03. The most severe graded abnormality was counted for each participant per test. ANC = absolute neutrophil count; Hb = hemoglobin; WBC = white blood cells |
First dose date up to the last dose date plus 30 days (maximum: 78.4 months)
|
Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher
Time Frame: First dose date up to the last dose date plus 30 days (maximum: 78.4 months)
|
Serum chemistry toxicity at anytime postbaseline was summarized according to the NCI CTCAE, version 4.03.
The most severe graded abnormality was counted for each participant per test.
ALT = alanine aminotransferase; ALP = alkaline phosphatase; AST = aspartate aminotransferase
|
First dose date up to the last dose date plus 30 days (maximum: 78.4 months)
|
Objective Response Rate (ORR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL)
Time Frame: From first dose date until first occurrence of CR or PR (or VGPR or MR for participants with LPL/WM) (up to approximately 7 years)
|
ORR: percentage of participants with complete response (CR) or partial response (PR) (or very good PR [VGPR] or minor response [MR] for participants with LPL/WM).
Per 2007 Cheson criteria, CR: complete resolution of all disease-related radiological abnormalities; PR: ≥50% reduction in sum of products (SPD) of the longest diameters of all index lesions, no new lesions; VGPR: >90% decrease from baseline (DFB) in IgM, and other criteria for CR met; MR: ≥25% but <50% DFB in IgM, no increase from baseline (IFB) in SPD of lesions, no new lesions.
Per IWCLL, CR: lymphocytes (Ly) <4*10^9/L, no lymphadenopathy, normal spleen and liver size, absence of disease, absolute neutrophil count (ANC) >1.5*10^9/L, platelets ≥100*10^9/L, hemoglobin (Hb) >110 g/L, bone marrow at least normocellular for age; PR: ≥2 of these: ≥50% decrease in Ly, lymphadenopathy, size of liver and spleen, bone marrow infiltrates; and ≥1 of these: ANC >1500/μL, platelets ≥100,000/µL, Hb >11 g/dL.
|
From first dose date until first occurrence of CR or PR (or VGPR or MR for participants with LPL/WM) (up to approximately 7 years)
|
Duration of Response (DOR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL)
Time Frame: From the date of first documentation of CR or PR (or VGPR or MR for participants with LPL/WM) to disease progression or death from any cause (up to approximately 7 years)
|
DOR was defined as the interval from first documentation of CR or PR (or VGPR or MR for participants with LPL/WM) to earlier of first documentation of definitive disease progression or death from any cause.
Per 2007 Cheson criteria, CR: complete resolution of all disease-related radiological abnormalities; PR: ≥50% reduction in SPD of longest diameters of all index lesions, no new lesions; VGPR: >90% DFB in IgM, and other criteria for CR met; MR: ≥25% but <50% DFB in IgM, no IFB in SPD of lesions, no new lesions.
Per IWCLL criteria, CR: Ly <4*10^9/L, no lymphadenopathy, normal spleen and liver size, absence of disease, ANC >1.5*10^9/L, platelets ≥100*10^9/L, Hb >110 g/L, bone marrow at least normocellular for age; PR: ≥2 of these: ≥50% decrease in Ly, lymphadenopathy, size of liver and spleen, bone marrow infiltrates; and ≥1 of these: ANC>1500/μL, platelets ≥100,000/µL, Hb >11 g/dL.
Disease progression: as defined in Outcome measure 1. DOR was analyzed using KM estimates.
|
From the date of first documentation of CR or PR (or VGPR or MR for participants with LPL/WM) to disease progression or death from any cause (up to approximately 7 years)
|
Time to Response (TTR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL)
Time Frame: From the first dose of study drug to the first documentation of CR or PR (or VGPR or MR for participants with LPL/WM) (up to approximately 7 years)
|
TTR was defined as the interval from the first dose of study drug to the first documentation of CR or PR (or VGPR or MR for participants with LPL/WM).
Per 2007 Cheson criteria, CR: complete resolution of all disease-related radiological abnormalities; PR: ≥ 50% reduction in SPD of the longest diameters of all index lesions, no new lesions; VGPR: >90% DFB in IgM, and other criteria for CR met; MR: ≥25% but <50% DFB in IgM, no IFB in SPD of lesions, no new lesions.
Per IWCLL criteria, CR: Ly <4*10^9/L, no lymphadenopathy, normal spleen and liver size, absence of disease, ANC >1.5*10^9/L, platelets ≥100*10^9/L, Hb >110 g/L, bone marrow at least normocellular for age; PR: ≥2 of these: ≥50% decrease in Ly, lymphadenopathy, size of liver and spleen, bone marrow infiltrates; and ≥1 of these: ANC >1500/μL, platelets ≥100,000/µL, Hb >11 g/dL.
|
From the first dose of study drug to the first documentation of CR or PR (or VGPR or MR for participants with LPL/WM) (up to approximately 7 years)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 14, 2013
Primary Completion (Actual)
September 14, 2017
Study Completion (Actual)
January 30, 2020
Study Registration Dates
First Submitted
February 13, 2013
First Submitted That Met QC Criteria
February 25, 2013
First Posted (Estimate)
February 27, 2013
Study Record Updates
Last Update Posted (Actual)
November 19, 2020
Last Update Submitted That Met QC Criteria
November 2, 2020
Last Verified
November 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Neoplasms by Site
- Hematologic Diseases
- Leukemia, Lymphoid
- Leukemia
- Leukemia, B-Cell
- Lymphoma, B-Cell
- Lymphoma
- Lymphoma, Large B-Cell, Diffuse
- Hematologic Neoplasms
- Lymphoma, Mantle-Cell
- Leukemia, Lymphocytic, Chronic, B-Cell
Other Study ID Numbers
- GS-US-339-0102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Follicular Lymphoma
-
Joseph TuscanoNational Cancer Institute (NCI); Genentech, Inc.; Pharmacyclics LLC.RecruitingAnn Arbor Stage II Follicular Lymphoma | Ann Arbor Stage III Follicular Lymphoma | Ann Arbor Stage IV Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
National Cancer Institute (NCI)TerminatedStage III Grade 1 Follicular Lymphoma | Stage III Grade 2 Follicular Lymphoma | Stage III Grade 3 Follicular Lymphoma | Stage IV Grade 1 Follicular Lymphoma | Stage IV Grade 2 Follicular Lymphoma | Stage IV Grade 3 Follicular LymphomaUnited States
-
National Cancer Institute (NCI)RecruitingRecurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterFox Chase Cancer Center; Pharmacyclics LLC.TerminatedFollicular Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade IIIaUnited States
-
Robert LowskyNational Cancer Institute (NCI); Janssen, LP; The Leukemia and Lymphoma Society; Rising Tide FoundationCompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
Fondazione Italiana Linfomi ONLUSCompletedFollicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade 3AItaly
-
Olivia Newton-John Cancer Research InstituteBristol-Myers Squibb; Barwon Health; Austin Health; Eastern Health; Fiona Stanley... and other collaboratorsRecruitingFollicular Lymphoma Stage II | Follicular Lymphoma Stage III | Follicular Lymphoma Stage IVAustralia
-
Epizyme, Inc.RecruitingFollicular Lymphoma | Relapsed/Refractory Follicular Lymphoma | Refractory Follicular LymphomaUnited States, China, Spain, France, Taiwan, United Kingdom, Australia, Korea, Republic of, Canada, Italy, Hungary, Poland, Belgium, Germany
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGrade 3a Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage III Grade 3 Follicular Lymphoma | Ann Arbor Stage...United States
-
Massachusetts General HospitalTG TherapeuticsTerminatedLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
Clinical Trials on Entospletinib MM
-
Gilead SciencesCompletedOncologyUnited States, New Zealand, Germany
-
Umeå UniversityGlaukos CorporationCompletedEye Diseases | Refractive Errors | Myopia | Corneal CrosslinkingSweden
-
Penumbra Inc.Active, not recruitingCerebral Hemorrhage | Intracerebral Hemorrhage | Brain Hemorrhage | Cerebral Parenchymal HemorrhageUnited States, Germany, Canada, Austria
-
Medtronic VascularCompletedCoronary Artery DiseaseUnited States
-
Sun Pharmaceutical Industries LimitedMoebius Medical Ltd.; Nordic Bioscience Clinical Development (NBCD)CompletedOsteoarthritis of KneeUnited States, Denmark, Hong Kong
-
University of California, IrvineUnited States Surgical CorporationCompletedMorbid ObesityUnited States
-
University of North Carolina, Chapel HillUniversity of Maryland, Baltimore; National Eye Institute (NEI); OrbisCompleted
-
University of Santiago de CompostelaCompletedGingival InflammationSpain
-
Cook Group IncorporatedCompletedPancreatic Neoplasms | Biliary Tract Neoplasms | Jaundice, ObstructiveUnited States
-
AO Clinical Investigation and Publishing DocumentationCompletedHip Fractures | Closed Fracture of HipIsrael, Austria, Switzerland, Germany, Belgium, Norway